|
|
Expressions and significance of β-catenin and Lgr5 in the progression of gastric cancer |
ZHENG Yanmin1, LIU Jiping2, ZHOU Xiaopin3, ZHAO Hongyan1, YU Meina1, NIU Haiyan1 |
1. Department of Gastroenterology, the Characteristic Medical Center of the Chinese People's Armed Police Force, Tianjin Key Laboratory of Hepatopancreatic Fibrosis and Molecular Diagnosis and Treatment, Tianjin 300162; 2. Jilin Armed Police Corps Hospital, Jilin 130052; 3. Department of Infection Control,Characteristic Medical Center of the Chinese People's Armed Police Force, Tianjin 300162 |
|
|
Abstract Objective To find out about the expressions and significance of β-catenin and Lgr5 in normal gastric mucosa, chronic superficial gastritis, chronic atrophic gastritis and gastric cancer. Methods A total of 105 inpatients and outpatients treated in our hospital between March 2014 and June 2015 were selected, including 23 cases of normal gastric mucosa, 25 cases of chronic superficial gastritis, 27 cases of chronic atrophic gastritis and 30 cases of gastric cancer. Immunohistochemistry was used to detect the expressions of β-catenin and Lgr5. Immunoreactivity was semi-quantitatively scored based on the percentage of positive cells and intensity of immunostaining. Results The positive rate of β-catenin was 8.7% in normal gastric mucosa, 28.0% in chronic superficial gastritis, 59.3% in chronic atrophic gastritis and 83.3% in gastric cancer, respectively, so the difference was statistically significant (P<0.05). The positive expression rate of Lgr5 was 13.0% in normal gastric mucosa, 32.0% in chronic superficial gastritis, 66.7% in chronic atrophic gastritis and 86.7% in gastric cancer, respectively. The difference was also of statistical significance (P<0.05). Conclusions β-catenin and Lgr5 are important markers to detect abnormal activation of Wnt/β-catenin signal pathway during the occurrence and development of gastric cancer.
|
Received: 03 June 2021
|
|
|
|
|
[1] |
Jemal A, Bray F, Center M M, et al. Global cancer statistics [J]. CA Cancer J Clin, 2011, 61(2): 69-90.
|
[2] |
王健力, 焦作义. Wnt/β-catenin信号通路及其抑制剂在消化道肿瘤中作用的研究进展[J]. 2020, 27(8): 938-945.
|
[3] |
裴志燕, 张岭漪. Wnt/β-catenin信号通路抑制剂在肝细胞癌中的研究[J]. 2020, 29(12): 1326-1330.
|
[4] |
Clevers H. Wnt/beta-catenin signaling in development and disease [J]. Cell, 2006, 127(3): 469-480.
|
[5] |
宿世琼, 倪 青, 侯 净, 等. miR-194对乳腺癌细胞增殖、侵袭迁移和Wnt /β-catenin信号通路的影响[J]. 中国免疫学杂志, 2020, 36(14): 1705-1709.
|
[6] |
陈 灿, 张艳玲, 刘小庆, 等. miR-182对直肠癌细胞增殖、侵袭及Foxo3a/Wnt/β-catenin通路的调节作用[J]. 实用肿瘤学杂志, 2020, 34(4): 328-333.
|
[7] |
周小嫔, 王佐妤, 刘彩红, 等. Lgr5在慢性浅表性胃炎中的表达[J]. 中国病理生理杂志, 2014, 30(12): 2272-2275.
|
[8] |
许良中, 杨文涛. 免疫组织化学反应结果的判定标准[J]. 中国癌症杂志, 1996, 6(4): 229-231.
|
[9] |
Tai D, Wells K, Arcaroli J, et al. Targeting the WNT signaling pathway in cancer therapeutics [J]. Oncologist, 2015, 20(10): 1189-1198.
|
[10] |
任重庆, 赵亚军, 廖文俊. 调控Wnt5a/Ca2+/Calcineurin/NFAT通路对黑素瘤细胞增殖、侵袭能力的影响[J]. 2016, 30(6): 555-558.
|
[11] |
王健力, 焦作义. Wnt/β-catenin信号通路及其抑制剂在消化道肿瘤中作用的研究进展[J]. 中国肿瘤生物治疗杂志, 2020, 27(8): 938-945.
|
[12] |
王元惠, 周振华. 吴茱萸碱对大肠癌细胞株HT29恶性生物学行为及Wnt/β-catenin信号通路的调控作用[J]. 海南医学院学报, 2016, 22(8): 729-731.
|
[13] |
蒋 琳, 廖君左, 赵妍丽, 等. FOXC2对人食管癌细胞增殖、迁移和侵袭的影响及相关机制研究[J]. 肿瘤预防与治疗, 2020, 33(8): 638-644.
|
[14] |
丁 锦, 詹乔乔, 何莲芝, 等. β-catenin、Wnt3a和Lgr5在不同宫颈病变组织中的表达及其意义[J]. 皖南医学院学报, 2017, 36(5): 436-439.
|
[15] |
蒋振华, 李修岭, 丁松泽, 等. Lgr5 与胃癌发生关系的研究进展[J]. 肿瘤预防与治疗, 2020, 33(8): 638-644.
|
[16] |
Alizadeh N R, Rafiei A, Abedian K S, et al. Comparison of leucine-rich repeat-containing G protein coupled receptor 5 expression in different cancer and normal cell lines[J]. Biomed Rep, 2016, 5(1): 130-132.
|
[17] |
Jia Y, Li Z, Cheng X, et al. Depletion of death-associated protein-3 induces chemoresistance in gastric cancer cells through the β-catenin/LGR5/Bcl-2 axis [J]. J Investig Med, 2019, 67(5): 856-861.
|
[18] |
高国安, 高 超. 胃癌组织中LGR5、HIF-1α的表达与临床意义[J]. 肿瘤药学, 2020, 10(4): 456-460.
|
[19] |
李京伟, 姜小艳, 陈玉琴, 等. Lgr5与Wnt/β-catenin通路在胃癌进程中的作用研究[J]. 中国实验诊断学, 2019, 23(12): 2055-2059.
|
[20] |
Mao J, Fan S, Ma W, et al. Roles of WNT/β-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment[J]. Cell Death and Disease, 2014, 5(1): e1039.
|
|
|
|